Recruiting

Observational Study

Sponsor:

The Cleveland Clinic

Code:

NCT05598879

Conditions

Breast Cancer

Hematologic Malignancy

Immune Checkpoint Inhibitor-Related Myocarditis

Cardiotoxicity

Cardiovascular Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

anonymized data collection during programmed surveillance clinical follow up

Study Details

Brief summary:

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.

Conditions

Breast Cancer

Hematologic Malignancy

Immune Checkpoint Inhibitor-Related Myocarditis

Cardiotoxicity

Cardiovascular Diseases

Study ID

NCT05598879

Start date

Jul 1, 2022

Status verified date

May, 2026

Completion date

Jul 1, 2029

Anticipated

Primary completion date

Jul 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • New cardio-oncology consultation for breast cancer patients, or
  • New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or
  • New cardio-oncology consultation for acute or chronic leukemia patients, or
  • New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or
  • New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.
  • All patients have to be 18 years old or older

Exclusion Criteria:

  • Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.
  • Minors less than 18 years old.
  • Inability or unwillingness to consent to participate

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Breast cancer

Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.

Hematological malignancies

Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.

Immune check point inhibitors

Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months

Interventions

anonymized data collection during programmed surveillance clinical follow up

anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform

Primary outcome measure

  • Cardiotoxicity [ Time Frame: 18 months of prospective follow up ]
  • New cardiovascular events [ Time Frame: 18 months of prospective follow up ]
  • Cardiovascular death. [ Time Frame: 18 months of prospective follow up ]

Central Contacts and Locations

Central contacts

Diego Sadler, MD FACC

5613898833sadlerd@ccf.org

Rohit Moudgil, MD PhD

216-445-1932moudgir@ccf.org

Locations

Cleveland Clinic Florida

Recruiting

Weston, Florida, United States, 33331

Contacts

Diego Sadler, MD FACC

561-389-8833sadlerd@ccf.org

More Information

Sponsor

The Cleveland Clinic

Last update posted

May 12, 2026

Last verified

May, 2026

Keywords

  • cardiotoxicity
  • Cancer related cardiovascular diseases
  • prospective registry
  • international collaboration
  • social determinants of health
  • health care disparities
  • real world data
  • cardiology-oncology team work

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by The Cleveland Clinic on 2026-05-12.